Ecological Modeling Sample Clauses

Ecological Modeling. The EAA will develop an ecological model to better understand biological and ecological relationships, processes, interactions, and responses over time of the systems being studied, and to predict ecological responses to changes in environmental conditions. The ecological model will address as many of the objectives and criteria listed in Subsection 6.3.3 of the HCP as possible. The EAA, through the Program Manager, will seek input from the Science Committee on the design and use of the model, and will seek input from the Implementing Committee on significant issues which arise in development of the model. The EAA, through the Program Manager, will also inform the SRP of planning and development related to the ecological model. The EAA will, as it determines to be appropriate, seek comment and evaluation from the SRP in order to help ensure that the SRP is able to rely on the model results in making its determinations pursuant to Subsection 7.13.7.
AutoNDA by SimpleDocs
Ecological Modeling. Washington is in the process of compiling spatial datasets to identify unique and vulnerable areas. The Biogeography Branch will support Washington’s efforts by identifying and evaluating datasets which may be helpful and deriving seabird species distribution models for numerous important species.

Related to Ecological Modeling

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Technical Standards Applicable to a Wind Generating Plant i. Low Voltage Ride-Through (LVRT) Capability A wind generating plant shall be able to remain online during voltage disturbances up to the time periods and associated voltage levels set forth in the standard below. The LVRT standard provides for a transition period standard and a post-transition period standard.

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

  • DISASTER RECOVERY AND BUSINESS CONTINUITY The Parties shall comply with the provisions of Schedule 5 (Disaster Recovery and Business Continuity).

  • Project Implementation 2. The Borrower shall:

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

Time is Money Join Law Insider Premium to draft better contracts faster.